• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.44% Nasdaq Down0.37%

    Dynavax Technologies Corporation (DVAX)

    27.89 Up 1.66(6.33%) 4:00PM EST
    |After Hours : 27.89 Down 0.00 (0.01%) 5:36PM EST
    ProfileGet Profile for:
    Dynavax Technologies Corporation
    2929 Seventh Street
    Suite 100
    Berkeley, CA 94710
    United States - Map
    Phone: 510-848-5100
    Fax: 510-848-1327
    Website: http://www.dynavax.com

    Index Membership:N/A
    Full Time Employees:197

    Business Summary 

    Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the United States. It development programs focus on the areas of vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The company’s product pipeline includes HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; SD-101, a CpG TLR9 agonist for the treatment of cancer immunotherapy that is in Phase I/II clinical trials; AZD1419, a drug candidate for the treatment of asthma, which has completed Phase I trial; DV1179, a TLR7/9 inhibitor that is in Phase I clinical trial for autoimmune or inflammatory conditions; and DV230-Nanoparticle, a second generation adjuvant that is in preclinical studies. It has a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease; and strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Dynavax Technologies Corporation

    Corporate Governance 
    Dynavax Technologies Corporation’s ISS Governance QuickScore as of Nov 1, 2015 is 10. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 10; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Eddie Gray , 55
    Chief Exec. Officer and Director
    Dr. Dennis A. Carson Ph.D., M.D., 68
    Co-Founder and Director
    Mr. Michael S. Ostrach J.D., 63
    Chief Financial Officer, Chief Bus. Officer, VP, Gen. Counsel and Sec.
    Mr. David F. Novack , 53
    Sr. VP of Operations and Quality
    Dr. Robert L. Coffman Ph.D., 68
    Chief Scientific Officer and Sr. VP
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders